Brian Zifcak

711 total citations
10 papers, 570 citations indexed

About

Brian Zifcak is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Brian Zifcak has authored 10 papers receiving a total of 570 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Pharmacology. Recurrent topics in Brian Zifcak's work include Histone Deacetylase Inhibitors Research (5 papers), Protein Degradation and Inhibitors (5 papers) and Ubiquitin and proteasome pathways (2 papers). Brian Zifcak is often cited by papers focused on Histone Deacetylase Inhibitors Research (5 papers), Protein Degradation and Inhibitors (5 papers) and Ubiquitin and proteasome pathways (2 papers). Brian Zifcak collaborates with scholars based in United States. Brian Zifcak's co-authors include Changgeng Qian, Xiong Cai, Cheng-Jung Lai, Guang-Xin Xu, Maria Samson, Ruzanna Atoyan, Da-Gong Wang, Ling Yin, Steven DellaRocca and Hui Qu and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Brian Zifcak

10 papers receiving 553 citations

Peers

Brian Zifcak

MB

ONCOL

OC

CTM

PRM

Henrik Moebitz Switzerland

Min‐Wu Chao Taiwan

Pascal Furet Switzerland

Lori K. Gavrin United States

Hai-Xiao Zhai

Laurie S. Kane-Carson United States

Amy M. Delaney United States

Julian Engel Germany

Stephen M. Courtney United Kingdom

Morgan Pellerano France

Henrik Moebitz Switzerland

Brian Zifcak

325 ×0.8

MB

119 ×0.9

ONCOL

105 ×0.8

OC

58 ×1.1

CTM

30 ×0.7

PRM

Citations per year, relative to Brian Zifcak Brian Zifcak (= 1×) peers Henrik Moebitz

Countries citing papers authored by Brian Zifcak

Since Specialization

Citations

This map shows the geographic impact of Brian Zifcak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Zifcak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Zifcak more than expected).

Fields of papers citing papers by Brian Zifcak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Zifcak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Zifcak. The network helps show where Brian Zifcak may publish in the future.

Co-authorship network of co-authors of Brian Zifcak

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Zifcak. A scholar is included among the top collaborators of Brian Zifcak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Zifcak. Brian Zifcak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Atoyan, Ruzanna, Maria Samson, Anna Walaszczyk, et al.. (2014). Abstract 917: Post-treatment changes in levels of TNF family ligands and XIAP may predict sensitivity to IAP antagonist CUDC-427. Cancer Research. 74(19_Supplement). 917–917. 1 indexed citations

2.

Wojakowska, Anna, Ruzanna Atoyan, Anas Younes, et al.. (2014). Abstract 1879: Dual function HDAC and PI3K inhibitor, CUDC-907 affects cancer cells and the tumor microenvironment in hematological malignancies. Cancer Research. 74(19_Supplement). 1879–1879. 2 indexed citations

3.

Wang, Jing, Anna Ma, Ruzanna Atoyan, et al.. (2013). CUDC-907, a Dual HDAC and PI3K Inhibitor, Potentially Targets Cancer Cells and The Microenvironment In Hematological Malignancies. Blood. 122(21). 4930–4930. 2 indexed citations

4.

Qian, Changgeng, Cheng-Jung Lai, Rudi Bao, et al.. (2012). Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling. Clinical Cancer Research. 18(15). 4104–4113. 188 indexed citations

5.

Wang, Da-Gong, Hui Qu, Ling Yin, et al.. (2012). Abstract 3744: Antitumor activity of CUDC-907, a dual PI3K and HDAC inhibitor, in hematological cancer models. Cancer Research. 72(8_Supplement). 3744–3744. 6 indexed citations

6.

Lai, Cheng-Jung, Rudi Bao, Xu Tao, et al.. (2010). CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity. Cancer Research. 70(9). 3647–3656. 182 indexed citations

7.

Bao, Rudi, Cheng-Jung Lai, Hui Qu, et al.. (2009). CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy. Clinical Cancer Research. 15(12). 4046–4057. 80 indexed citations

8.

Bao, Rudi, Cheng-Jung Lai, Da-Gong Wang, et al.. (2009). Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non–small cell lung cancer. Molecular Cancer Therapeutics. 8(12). 3296–3306. 47 indexed citations

9.

Cochran, Edward, James L. Ellis, David S. Garvey, et al.. (2007). Structure-Based Design, Synthesis, and Biological Evaluation of Indomethacin Derivatives as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors. Journal of Medicinal Chemistry. 50(25). 6367–6382. 45 indexed citations

10.

Dhawan, Vijay, David J. Schwalb, Matthew J. Shumway, et al.. (2005). Selective nitros(yl)ation induced in vivo by a nitric oxide-donating cyclooxygenase-2 inhibitor: a NObonomic analysis. Free Radical Biology and Medicine. 39(9). 1191–1207. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact